Fundraising FoxAllevion Therapeutics
Irvine, US · Founded 2018 · Delaware corporation
Find your way into Allevion Therapeutics
Sign up to see every warm intro you have to Allevion Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Allevion Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Allevion Therapeutics is a medical device company developing technologies in the healthcare and medtech space. Its team has a background in cardiac arrhythmia, atrial fibrillation, and neurological/movement disorder treatments.
Founders & leadership
PS
Pintoo ShahMr. Shah serves as an executive officer of the company.
S
ShawnCEO & Chairman
NH
Neal HermanowiczNamed on SEC filing
SM
Shahram MoaddebNamed on SEC filing
Board
JW
Jack WangMr. Wang serves as a director of the company.
MR
Mahmood RazaviMr. Razavi serves as a diector of the company.
RT
Roy TanakaMr. Tanaka serves as a director of the company.
RW
Randy WernethMr. Werneth serves as a director of the company.
DD
Dan DearenMr. Dearen serves a director of the company.
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 2 rounds · 2021–2024
▶$1.5MraisedMar 2024 · 7 investors · BiotechnologyRule 506(b)
▶$1.5MraisedMar 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roy TanakaDirector
- Dan DearenDirector
- Shinya MiikeDirector
- Neal HermanowiczExecutive Officer
- Jack WangDirector
- Mahmood RazaviDirector
- Pintoo ShahExecutive Officer
- Randy WernethDirector
- Shahram MoaddebExecutive Officer, Director, Promoter
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Minimum investment
- $25K
- Proceeds to insiders
- $300K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedJul 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedJul 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jack WangDirector
- Mahmood RazaviDirector
- Roy TanakaDirector
- Randy WernethDirector
- Pintoo ShahExecutive Officer
- Dan DearenDirector
- Neal HermanowiczExecutive Officer
- Shahram MoaddebExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $1M
- Proceeds to insiders
- $200K
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Allevion Therapeutics do?
- Allevion Therapeutics is a medical device company developing technologies in the healthcare and medtech space. Its team has a background in cardiac arrhythmia, atrial fibrillation, and neurological/movement disorder treatments.
- How much funding has Allevion Therapeutics raised?
- Allevion Therapeutics has disclosed $2.5M raised across 2 rounds.
- Where is Allevion Therapeutics headquartered?
- Allevion Therapeutics is headquartered in Irvine, US.